Interv Akut Kardiol 2012; 11(3-4): 144-147

Dual antiplatelet therapy in patients on long-term anticoagulation

Ivo Varvařovský
Kardiologické centrum Agel, Pardubice

Anticoagulant therapy of the patients with atrial fibrillation decreases the risk of systemic embolization and is an effective long-term

treatment for patients with mechanical valve prosthesis and pulmonary embolism. For these patients, dual antiplatelet therapy is considered

as ineffective treatment, but is proved to be essential for patients after acute coronary syndrome and after coronary angioplasty.

Anticoagulant therapy together with dual antiplatelet („triple therapy“) increase substantially the risk of serious bleeding. Nevertheless,

triple therapy seems to be better choice, especially for the first months after coronary event or PCI in high-risk patients, but data are still

insufficienct to take a definitive stand on this topic.

Keywords: aspirin, clopidogrel, warfarin, coronary angioplasty, acute coronary syndrome

Published: May 11, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Varvařovský I. Dual antiplatelet therapy in patients on long-term anticoagulation. Interv Akut Kardiol. 2012;11(3-4):144-147.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Budnitz DS, Pollock DA, Weidenbach KN. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006; 296: 1858-1866. Go to PubMed...
    2. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167: 1414-1419. Go to original source... Go to PubMed...
    3. Flaherty ML, Kissela B, Woo D. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 2007; 68: 116-121. Go to original source... Go to PubMed...
    4. ACTIVE investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrilation in the ACTIVE W: a randomised controlled trial. Lancet 2006; 367: 1903-1912. Go to original source... Go to PubMed...
    5. Lip GY, Niuewlaat R, Pisters R. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrilation using a novel risk factor-based approach. Chest 2010; 137: 263-272. Go to original source... Go to PubMed...
    6. Wang TY, Chen AY, Peterson ED. Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative. Eur Heart J 2008; 29: 1103-1109. Go to original source... Go to PubMed...
    7. Pelc-Nowicka A, Bryniarski L, Mirek-Bryniarska E. Dual antiplatelet therapy and antithrombotic treatment in patients with acute coronary syndrome. Kardiol Pol 2009; 67: 1335-1341. Go to PubMed...
    8. Karjalainen PP. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007; 28: 726-732. Go to original source... Go to PubMed...
    9. Ruiz-Nodar JM. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrilation undergoing percutaneous coronary intervention and stent implantation. J Am Coll Cardiol 2008; 51: 818-825. Go to original source... Go to PubMed...
    10. Ruiz-Nodar JM, Marin F, Manzano-Fernandez S. An evaluation of the CHADS2 stroke risk score in patients with atrial fibrilation who udergo percutaneous coronary revascularization. Chest 2011; 139: 1402-1409. Go to original source... Go to PubMed...
    11. Zhao JH, Zheng ZT, Wang ZH. Triplet therapy rather than triple threat. Chest 2011; 139: 260-270. Go to original source... Go to PubMed...
    12. Gao F, Zhou YJ, Wang ZJ. Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation. Int J Cardiol 2011; 148: 96-101. Go to original source... Go to PubMed...
    13. Sambola A, Ferreira-Gonzalez I, Angel J. Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study. Heart 2009; 95: 1483-1488. Go to original source... Go to PubMed...
    14. Lip GYH, Huber K, Andreotti F. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting. Eur Heart J 2010; 31: 1311-1318. Go to original source... Go to PubMed...
    15. Čihák R, Heinc P, Haman L. Fibrilace síní. CorVasa 2011; 53(Suppl 1): 27-49. Go to original source...
    16. Camm JA, Kirchhof P, Lip YH. Guidelines for the management of atrial fibrillation. Eur Heart J 2010; 31: 2369-2429. Go to original source... Go to PubMed...
    17. Wallentin L, Yusuf S, Ezekowitz MD. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983. Go to original source... Go to PubMed...
    18. Oldgren J, Budaj A, Granger CB. Dabigatran vs placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32: 2781-2789. Go to original source... Go to PubMed...
    19. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;Jan9. E-pub ahead of print. Go to original source... Go to PubMed...
    20. Alexander JH, Becker RC, Bhatt DL. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the APPRAISE trial. Circulation 2009; 119: 2877-2885. Go to original source... Go to PubMed...
    21. Alexander JH, Lopes RD, James S. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699-708. Go to original source... Go to PubMed...
    22. Mega JL, Braunwald E, Mohanavelu S. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46). Lancet 2009; 374: 29-38. Go to original source... Go to PubMed...
    23. Mega JL, Braunwald E, Wiviott SD. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19. Go to original source... Go to PubMed...
    24. Dewilde W, Ten Berg JM. Design and rationale of the WOEST trial. Am Heart J 2009; 158: 713-718. Go to original source... Go to PubMed...
    25. Schoming A, Sarafoff N, Seyfarth M. Triple antithrombotic management after stent implantation: when and how?. Heart 2009; 95: 1280-1285. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.